年龄-白细胞-国际标准化比值评分(ALIS):热射病急诊神经预后评估的床旁三参数工具
该回顾性多中心研究基于年龄、炎症指标和凝血结果构建了ALIS评分,用于预测热射病患者出院时神经预后。共纳入235例热射病患者,按7:3分为推导队列(n=165)和验证队列(n=70)。推导队列中36例出院时预后不良,多因素回归确定年龄、白细胞计数和INR为独立危险因素并构建ALIS。推导队列和验证队列中ALIS预测不良结局的AUC分别为0.817和0.820,与qSOFA(AUC=0.812、0.680)和APACHE II(AUC=0.802、0.762)相似,但ALIS评估更快速简单。ALIS>2分的热射病患者不良结局发生率显著高于ALIS≤2分者。
要点
- ALIS由年龄、白细胞计数和国际标准化比值(INR)三项构成,用于热射病患者出院时神经预后判断。
- 推导队列ALIS预测不良神经结局AUC=0.817,验证队列AUC=0.820。
- 推导队列qSOFA的AUC=0.812、APACHE II的AUC=0.802;验证队列qSOFA的AUC=0.680、APACHE II的AUC=0.762。
- ALIS>2分的热射病患者不良结局发生率显著高于ALIS≤2分者。
- ALIS评估比APACHE II更快速简单,零成本计算,作者认为尤其适合资源受限的急诊环境。
适用人群与场景
- 热射病(HS)患者,研究纳入235例,推导队列165例、验证队列70例。
诊断标准与关键阈值
- ALIS评分由年龄、白细胞计数、国际标准化比值(INR)三项独立危险因素构成,ALIS>2分定义为高危阈值(原文以ALIS>2与ALIS≤2分组比较不良结局)。
研究设计与关键结果
- 研究类型:回顾性多中心研究,共纳入235例热射病患者,按7:3分为推导队列(n=165)和验证队列(n=70)。
- 推导队列中36例患者出院时预后不良。
- 多因素回归分析确定年龄、白细胞计数和国际标准化比值(INR)为预测不良结局的独立危险因素,据此构建ALIS评分。
- 推导队列ALIS预测不良结局AUC=0.817,验证队列AUC=0.820。
- 推导队列qSOFA的AUC=0.812、APACHE II的AUC=0.802;验证队列qSOFA的AUC=0.680、APACHE II的AUC=0.762。
- ALIS评估比APACHE II更快速简单。
- ALIS>2分的热射病患者不良结局发生率显著高于ALIS≤2分者。
证据类型、等级与局限
- 证据类型:回顾性多中心研究(推导与验证队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ALIS是可在临床实施的决策支持工具,在热射病床旁预后判断方面显著优于传统严重程度评分。
- 作者认为ALIS零成本计算和床旁适用性使其尤其适合资源受限的急诊环境。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study was to develop and validate the age-leukocyte-international normalized ratio score (ALIS), a novel triparametric prognostic tool integrating geriatric vulnerability, systemic inflammation, and consumptive coagulopathy, to predict neurological outcomes in heat stroke (HS) patients.
METHODS: This retrospective, multicenter study was performed to establish a novel scoring system based on age, inflammation indicators and coagulation test results, with a validation cohort employed to verify the reliability. The primary endpoint was neurological prognosis at discharge, and secondary endpoint included multiple organ dysfunction syndrome, requirement for mechanical ventilation, continuous renal replacement therapy, admission to the intensive care unit, and death at discharge. Prognostic discrimination capacity was evaluated using receiver operating characteristic curve analysis with Delong's test to compare the performance against quick Sequential Organ Failure Assessment (qSOFA) and Acute Physiology and Chronic Health Evaluation (APACHE II) scores.
RESULTS: Overall, 235 patients with HS were recruited, and allocated to the derivation (n = 165) and validation (n = 70) cohort at a ratio of 7:3. In the derivation cohort, 36 patients had poor outcomes post-discharge. Multivariate regression analysis identified age, leukocyte count, and international normalized ratio as independent risk factors predicting poor outcomes, which were used to construct the new scoring system (ALIS). In the derivation and validation cohort, the ability of ALIS(AUC = 0.817, 0.820, respectively) to predict poor outcome was similar to qSOFA(AUC = 0.812, 0.680, respectively) and APACHE II (AUC = 0.802, 0.762, respectively). However, the assessment of ALIS was quicker and simpler than APACHE II. Among patients with HS, those with ALIS >2 had a significantly higher incidence of adverse outcome than those with ALIS ≤2.
CONCLUSION: The ALIS is a clinically implementable decision-support tool that significantly outperforms conventional severity scores in bedside prognostication of HS outcomes. Its zero-cost computation and bedside applicability make it particularly suited for resource-constrained emergency settings.
参考来源
- Zhou F, Zhu X, Duan H, et al. Age-leukocyte-international normalized ratio score (ALIS): A bedside triparametric tool for neurological prognostication in heat stroke emergencies. Am J Emerg Med. 2025. PMID: 40633487. doi:10.1016/j.ajem.2025.06.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。